HRT Therapy – Delving Into The Finer Nuances – Part II

HRT and related endometrial cancer risk
Low-dosage vaginal oestrogens are also used in the treatment of postmenopausal women having frequent urinary tract infection and aggravating urinary symptoms after the underlying pathology has been ruled out. There is no proof of local estrogen treatment related to any major risks. Though, when there is protracted use in cases of intact uterus, then it is advocated that an assessment of the endometrial pathology be conducted.

However, the inclusion of progesterone to the oestrogen therapy lowers the chances of endometrial disease, though schedules must normally contain a minimum of ten days in every menstrual cycle.

Postmenopausal women that have been on a course of sequential combo of oestrogen-progestogen treatment for greater than 5 years and desire to carry on with it are at a raised likelihood of endometrial carcinoma. Such women are suggested to opt for a change to a continual combo regimen that appears to present no added risk.

Few studies have indicated a probable rise in the number of ovarian cancer cases among those women on HRT. Though, there is a dearth of adequate proof from high-standing research to be able to conclude the effects of HRT on ovarian cancer.

Use of progesterone is particularly for providing protection to the endometrium. The administration of vaginal progesterone and LNG-IUS or levonorgestrel releasing intrauterine system usage appears to hold immense potential but anticipating greater definitive study for corroboration.

HRT and related Venous Thromboembolism (VTE) risks
The likelihood of VTE among women starting HRT is augmented in the presence of personal past of thrombophilias, past VTE episodes and family past in 1st or 2nd degree relative. HRT must be circumvented among women with multifarious pre-existent risk elements for VTE.

Transdermal oestrogen are linked with lower likelihood of VTE when evaluated against oral oestrogen treatment and deemed as an effectual substitute. Lesser HRT dosages might also have lesser VTE risk as compared to higher dosages. It is suggested that when a women who is on HRT course develops DVT, then immediate cessation of HRT is applied.

Topical treatment has an obvious benefit of lesser occurrence of VTE and lowering dosage when dealing with urogenital symptoms.

HRT and it effects on cognitive functioning
Latest randomized controlled WHIMS or Women’s Health Initiative Memory Study trial conducted on elderly women that were 65 years or more cited that HRT had no useful effect on cognitive function.

Additionally, HRT has not been noted to be of any major usefulness in treating Alzheimer’s disease.

HRT and its effects on depression
HRT is not advisable for usage and not authorized as a primary therapy for clinically major depression or dementia. Few though not all research have revealed that HRT appears to uplift depressive moods among menopausal women.

Few research studies have indicated that the anti-depressants like venlafaxine, paroxetin and fluoxetine are unauthorized treatments choices for women having hot flushes and in women who are not participants for oestrogen therapy. An advantage of nearly 50% is noted in trials of several unconventional preparations recommended for vasomotor signs, even in placebo sets. Likewise, there is no believable proof to back the usage of food supplements and herbs.

Read more at: HRT Therapy – Delving Into The Finer Nuances – Part I

Popularity: 6% [?]